With a boost from an extra selling day during the third quarter, the US OrthoBio Market continues to be healthy, with Q319 revenue up +5.8% YOY. Year-to-date revenue is up +5.5% compared to the same time period for 2018. In addition to the specific factors that were discussed in the Q219 OrthoBio Recap, the segment’s success may be attributed to robustness in the broader economy and more people feeling comfortable scheduling procedures. As reported in Needham’s Q319 Review, in Q319 vs. Q219, overall orthopedic market growth improved to 5.0% vs. 3.1%, with spine improving to ...Among the many topics covered in the complete, comprehensive Q319 OrthoBio Market Recap* are:
5 min read
SmartTRAK predicts Orthobiologic’s top market and technology trends to watch in 2019
So what did we see in store for Orthobiologics? Here are SmartTRAK’s predictions for the top market and technology trends to watch:
Balancing Sales Growth Trajectory and Portfolio Reshaping
As competition heats up, companies will continue to identify tailwinds and headwinds that sway sales growth and will reshape portfolios accordingly. Sustaining above-market growth rates will take creativity, especially in stagnate markets like spine or in areas that face access challenges. Expect focused efforts around adding/expanding higher growth-higher margin products, shedding lower growth-lower margin product lines and expanding market penetration or margins for the “low-hanging fruit” prospects....
5 min read
SmartTRAK reports that Q219 performance in the OrthoBio market was strong, up 6% YoY, exceeding SmartTRAK expectations. As expected, Medtronic was the overall OrthoBio market leader, followed by DePuy Synthes and Stryker. Overall, all OrthoBio technologies grew year-over-year except for Spinal Constructs, Soft Tissue Augmentation and Synthetic Cartilage. Although the Spine market has stabilized, Spinal Constructs continues to slowly lose share due to...
4 min read
Advanced, higher priced biologics push the US OrthoBio Market higherBased on Q418/FY18 SmartTRAK Financial Dashboard reporting:
- US Bone Replacement grew +2.3% YoY, with FY18 revenues up +2.7%.
- US Cartilage Replacement increased 55.7% YoY, with FY18 revenues up 34.7%.
- US Soft Tissue Augmentation grew 2.3%, with FY18 revenues growing 9.2%.
- US Tendon Allografts posted an 8.4% YoY increase, with FY18 revenues up +3.9% YoY
- US Meniscal Implant market, with robust growth, was up 15.6% YoY for Q418 with FY18 revenues increasing by 3.0%.
Among the many topics covered in the Q418/FY18 OrthoBio Market Recap are:
5 min read
Stem cell “secretome” is the latest advancement in regenerative medicine. Will it become the heart of tissue regeneration? SmartTRAK interviewed Dr. Robert Keller, Ph.D, Chief Science Officer of Axolotl Biologix to learn more about the Company’s platform and future plans.
The core of regenerative medicine and leveraging the abilities of stem cells and their products to repair diseased or damaged tissues has focused in two main areas, harvesting progenitor cells and the “paracrine effect” of the stem cell secretome.
Recent studies suggest that the benefits of stem cell therapy and the underlying mechanism of repair might relate more to a paracrine modulatory effect rather than the replacement of damaged cells at the site. The secreted factors from the transplanted stems cells have been shown to trigger the patient's own cells to repair the tissue themselves.
One company that is harnessing the power of the stem cell secretome is Axolotl Biologics. Started in 2016, Axolotl Biologics offers human amnion-derived mesenchymal stromal cell (hAMSCs) conditioned medium that contains hAMSCs paracrine factors which can be used in various applications in orthopedics, wound care, pain management, ophthalmology, cardiovascular and cosmetics.
At the 6th ICRS Summit, Bio-Orthopaedics in Sports Medicine, held in San Diego, January 17 and 18, 2019, SmartTRAK caught up with Axolotl Biologix’ Chief Science Officer, Robert Keller, Ph.D. to discuss regenerative medicine and the Company’s progress.
Click on the video below to view the fascinating interview, scroll down to read a transcript of the interview or download a PDF of the interview by clicking the link below.
4 min read
Acquisitions and Partnerships are Highpoints in Q318
SmartTRAK reports that the US OrthoBio Market (comprised of Bone Replacement, Cartilage, Soft Tissue and Meniscus) is growing at 4.1% YTD. For Q318, there were no surprises and the segment reached...
1 min read
Irrespective of Market Challenges, Orthobiologics Remain Strong
While SmartTRAK saw a strong start in the beginning of the year, Orthobiologics didn’t see the typical Q2 bump. This trend was primarily driven by lower bone replacement revenues. Revenues from the sports medicine segments partially offset the bone replacement declines, with strong performances in Cartilage Replacement and Soft Tissue Augmentation.
Among the many topics covered in the full Q218 Ortho Market Recap are:
12 min read
Cerapedics’ CEO Glen Kashuba and President and COO Jeff Marx, Ph.D. discuss the future of the bone graft substitutes and the uniqueness of i‑FACTOR Peptide Enhanced Bone Graft, a small peptide technology in an interview with Kim French, Sr. Analyst, SmartTRAK Orthbio.
A transcript of SmartTRAK's interview with Glen Kashuba and Jeff Marx is below, or click on the following video to listen to the interview.
3 min read
Up 3.4% YoY, the OrthoBio market is off to a good start. Companies that are surpassing growth expectations tend to have differentiated products, focused efforts and incremental pull through from synergistic sales strategies. Market subtleties like reimbursement, pricing pressures and market loss due to newer competition continue to afflict some companies and segments...
Among the many topics covered in the full Q118 OrthoBio Market Recap are:
1 min read
SmartTRAK is excited to be attending TOBI 2018 - The 9th Annual PRP & Regenerative Medicine Symposium, Workshops & Cadaver Labs - June 7-9 at Wynn, Las Vegas, Nevada.